Definium Therapeutics Inc（DFTX）财务数据DFTXDefinium Therapeutics Inc

Evaluating the bottom line, Definium Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -64.09%, provide a clear picture of how effectively DFTX converts its operational activities into shareholder value.

In the context of the broader market, DFTX competes directly with industry leaders such as LGND and AMRX. With a market capitalization of $5.73B, it holds a significant position in the sector. When comparing efficiency, DFTX's gross margin of N/A stands against LGND's 82.24% and AMRX's 42.01%. Such benchmarking helps identify whether Definium Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Definium has been experiencing significant losses, with a net income of -158,986,000 in Q2 2026 and an EPS of -1.44. Despite these losses, the company has shown a strong current ratio of 6.95, indicating good short-term financial health.